My favorite story as a 38-year-old man living with Spinal Muscular Atrophy Type II, a form of Muscular Dystrophy that renders ...

Sarepta Therapeutics, Inc. SRPT reported first-quarter 2025 adjusted loss of $3.42 per share against the Zacks Consensus ...

The symposium took place on 18 th March 2025, as part of the Muscular Dystrophy Association (MDA) Clinical & Scientific ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...